Related Experiment Video
Updated: Apr 30, 2026
09:15
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
3.8K
Push and release: TLR9 activation plus STAT3 blockade for systemic antitumor immunity.
Marcin Kortylewski1, Ya-Huei Kuo2
1Department of Cancer Immunotherapeutics & Tumor Immunology; Beckman Research Institute; City of Hope National Medical Center; Duarte, CA USA.
Oncoimmunology
|May 7, 2014
Summary
This study shows that activating Toll-like receptor 9 (TLR9) and blocking signal transducer and activator of transcription 3 (STAT3) in leukemia boosts immune response. This "Push & Release" strategy enhances cancer immunotherapy by enabling T cell-mediated tumor eradication.
Area of Science:
- Immunology
- Oncology
- Biochemistry
Background:
- Anticancer immunotherapy requires both immunostimulation ("push") and immune checkpoint blockade ("release").
- Signal transducer and activator of transcription 3 (STAT3) plays a role in immune evasion in hematological malignancies.
Purpose of the Study:
- To investigate the therapeutic potential of a combined "Push & Release" strategy against hematological malignancies.
- To evaluate the efficacy of activating Toll-like receptor 9 (TLR9) and blocking STAT3 in enhancing anti-leukemia immune responses.
Main Methods:
- Activation of Toll-like receptor 9 (TLR9) in leukemic cells.
- Specific blockade of signal transducer and activator of transcription 3 (STAT3) in leukemic cells.
- Assessment of leukemic cell immunogenicity and CD8+ T cell-mediated anti-tumor activity.
Main Results:
- Activating TLR9 and blocking STAT3 significantly enhanced leukemic cell immunogenicity.
- The combined strategy promoted CD8+ T cell-mediated eradication of leukemic cells.
- This approach demonstrated therapeutic potential in preclinical models of hematological malignancies.
Conclusions:
- The "Push & Release" strategy, involving TLR9 activation and STAT3 blockade, is a promising approach for enhancing anticancer immunotherapy in hematological malignancies.
- Targeting both immune stimulation and immune evasion pathways offers a novel therapeutic avenue for leukemia treatment.
